Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

In this study the effectiveness of degarelix, a long acting GnRH antagonist administered in a unique administration of 20 mg the first day of menstrual cycle, to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS women at risk to develop OHSS.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
• Treatments: Cetrorelix

Criteria

Inclusion Criteria:

• women with PCOS

• previous OHSS

• Infertility

Exclusion Criteria:

• more than 38 years old

• Body mass index pore than 30

• other systemic diseases